Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:05:00 EDT Sun 13 Jul 2025
Enter Symbol
or Name
USA
CA



Q:RLAY - RELAY THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
RLAY - Q0.23.50·3.900.53.60-0.13-3.51,034.43,5104,3583.67  3.70  3.5610.72  1.77519:59:41Jun 1115 min RT 2¢

Recent Trades - Last 10 of 4358
Time ETExPriceChangeVolume
19:59:41Q3.58-0.154
19:35:32Q3.58-0.1532
17:37:56Q3.65-0.08100
17:29:24Q3.66-0.07350
17:29:24Q3.66-0.07100
17:23:04Q3.66-0.074
17:23:04Q3.67-0.0696
17:21:59Q3.70-0.03100
16:22:32Q3.72-0.011
16:11:52Q3.60-0.1329,866

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-11 16:05U:RLAYNews ReleaseRelay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
2025-06-02 07:00U:RLAYNews ReleaseRelay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025
2025-05-29 16:05U:RLAYNews ReleaseRelay Therapeutics to Participate in Two Upcoming Investor Conferences in June
2025-05-08 16:06U:RLAYNews ReleaseRelay Therapeutics to Participate in Two Upcoming Investor Conferences
2025-05-05 16:05U:RLAYNews ReleaseRelay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates
2025-04-28 16:06U:RLAYNews ReleaseRelay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025
2025-02-26 16:05U:RLAYNews ReleaseRelay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
2025-02-24 16:06U:RLAYNews ReleaseRelay Therapeutics to Participate in Two Upcoming Investor Conferences
2025-02-19 16:06U:RLAYNews ReleaseRelay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025
2025-01-07 16:05U:RLAYNews ReleaseRelay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
2024-12-11 06:00U:RLAYNews ReleaseRelay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
2024-12-09 16:06U:RLAYNews ReleaseRelay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium
2024-12-03 08:01U:RLAYNews ReleaseElevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
2024-12-03 08:00U:RLAYNews ReleaseRelay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
2024-11-07 16:05U:RLAYNews ReleaseRelay Therapeutics to Participate in Upcoming Investor Conferences
2024-11-06 16:05U:RLAYNews ReleaseRelay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights
2024-10-30 16:05U:RLAYNews ReleaseRelay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024
2024-09-10 20:22U:RLAYNews ReleaseRelay Therapeutics Announces Pricing of Public Offering of Common Stock
2024-09-09 16:34U:RLAYNews ReleaseRelay Therapeutics Announces Proposed Public Offering of Common Stock
2024-09-09 06:55U:RLAYNews ReleaseRelay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival